ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2848

Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)

Stefano Alivernini1, Barbara Tolusso 1, Marco Gessi 2, Maria Rita Gigante 1, Luca Petricca 1, Clara Di Mario 3, Simone Perniola 1, Anna Laura Fedele 1, Giusy Peluso 4, Laura Bui 2, Annunziata Capacci 1, Francesco Federico 2, Gianfranco Ferraccioli 3 and Elisa Gremese 1, 1Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 2Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 3Institute of Rheumatology - Università Cattolica del Sacro Cuore, Rome, Italy, 4Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biomarkers, histopathologic and Clinical Response, rheumatoid arthritis, synovium

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T114: RA – Diagnosis, Manifestations, & Outcomes IV: Outcomes (2846–2851)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Ultrasound (US)-guided minimally-invasive Synovial Tissue (ST) biopsy is a well tolerated procedure for basic and translational studies on chronic inflammatory joint diseases as Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Spondyloarthritis (SpA). The aim of the study was to evaluate the utility of histopathologic criteria to differentiate US-guided ST biopsies in daily clinical care in relation to diagnosis, disease characteristics, US parameters and treatment response in a large single center ST biopsy Unit.

Methods: 1064 patients [545 RA, 167 PsA, 75 SpA, 199 Undifferentiated Peripheral Inflammatory Arthritis (UPIA), 18 crystal arthritis, 26 connective tissue diseases and 34 osteoarthritis (OA) respectively] who underwent US-guided ST biopsy were enrolled. US parameters (Synovial Hyperthrophy and Power Doppler signal respectively) were recorded for each biopsied joint. RA, PsA and SpA patients were stratified based on disease activity phase (naive to DMARDs, DMARDs resistant and in sustained remission, respectively). Clinical, demographic and immunological characteristics were recorded for each patient. All ST FFPE specimens were routinely processed and stained with H&E and classified by a pathologist, blinded to clinical characteristics, using the Krenn score to assess the degree of ST inflammation1. Moreover, the presence/absence of lymphocytes, plasmacells, granulocytes and oedema was assessed for each ST. All naive to treatment RA were treated according to the T2T scheme and followed for at least 12 months and DAS remission rate was recorded.

Results: In the cohort, the distribution of synovitis score was significantly different among patients with inflammatory chronic diseases (RA, PsA, SpA and UPIA respectively) compared to OA (ANOVA Test p< 0.001). Moreover, Krenn score directly correlated with synovial hyperthrophy (R=0.36;p< 0.001) and Power Doppler signal (R=0.40;p< 0.001) of the biopsied joint. Considering the RA cohort, naive RA showed a higher Krenn score compared to resistant RA (p< 0.001) and RA in sustained clinical and US remission (p< 0.001), directly correlating with DAS28 (R=0.51;p< 0.001). Moreover, ACPA and RF positivity was related to the Krenn score and to ST plasmacells presence at RA onset (p< 0.05 and p< 0.001, respectively) but not at the time of DMARDs-failure or sustained remission achievement (p >0.05 for both). Stratifying naive RA based on disease duration at ST biopsy, naive RA with symptoms duration >1 year, showed higher Krenn score compared to those with symptoms duration < 3 months (p< 0.001). Finally, logistic regression analysis revealed that, in naive RA, Krenn score ≥4.5 at baseline is an independent factor of no DAS remission achievement within 12 months [OR(95%CI):0.37(0.20-0.67)p< 0.001].

Conclusion: Krenn score is a reliable tool for the semi-quantitative assessment of ST inflammation on US-guided ST biopsies being differentially distributed among various chronic inflammatory joint diseases and contingent to disease phase, autoimmune profile and therapeutic response in RA.

References. 1Krenn V, et al. Histopathology 2006


Disclosure: S. Alivernini, None; B. Tolusso, None; M. Gessi, None; M. Gigante, None; L. Petricca, None; C. Di Mario, None; S. Perniola, None; A. Fedele, None; G. Peluso, None; L. Bui, None; A. Capacci, None; F. Federico, None; G. Ferraccioli, None; E. Gremese, AbbVie, 5, 8, Abbvie, 5, 8, BMS, 5, 8, Bristol-Myers Squibb, 5, 8, Celgene, 5, 8, Jannsen, 5, 8, Lilly, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Sandoz, 5, 8, UCB, 5, 8.

To cite this abstract in AMA style:

Alivernini S, Tolusso B, Gessi M, Gigante M, Petricca L, Di Mario C, Perniola S, Fedele A, Peluso G, Bui L, Capacci A, Federico F, Ferraccioli G, Gremese E. Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/semiquantitative-assessment-of-synovial-inflammation-on-us-guided-synovial-membrane-biopsy-is-contingent-to-disease-phase-autoimmune-profile-and-treatment-response-in-rheumatoid-arthritis-large-sing/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/semiquantitative-assessment-of-synovial-inflammation-on-us-guided-synovial-membrane-biopsy-is-contingent-to-disease-phase-autoimmune-profile-and-treatment-response-in-rheumatoid-arthritis-large-sing/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology